Dulaglutide
Dulaglutide is not a peptide. It is indexed alongside Incretin receptor agonists because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Dulaglutide is a GLP-1 analogue fused to a modified immunoglobulin Fc fragment, a fusion protein rather than a peptide; PubChem returned no compound record for the name. The Drugs@FDA register returned an approved biologics application under this generic name, which is recorded in the regulatory status field and is not what this page describes. The retrieved literature is the AWARD trial programme in type 2 diabetes: 2014 Diabetes Care papers report comparisons with metformin, sitagliptin and exenatide, a 2014 Lancet paper compares once-weekly dulaglutide with once-daily liraglutide, a 2015 Diabetes Care paper compares it with insulin glargine, and a 2018 Lancet Diabetes and Endocrinology paper reports it as add-on therapy to SGLT2 inhibitors.
Outcome records include the 2019 Lancet REWIND cardiovascular outcomes trial, a 2019 exploratory analysis of renal outcomes from the same trial, a 2020 Lancet Neurology exploratory analysis of cognitive impairment, a 2018 Lancet Diabetes and Endocrinology paper in moderate-to-severe chronic kidney disease, and the 2018 SUSTAIN 7 comparison with semaglutide.
[2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]Reported mechanism
A GLP-1 receptor agonist fusion protein; the retrieved records are clinical trials in type 2 diabetes rather than receptor pharmacology.
[8, 5]Taken from the cited 2019 Lancet REWIND and 2014 Lancet AWARD-6 titles together with the class definition.
Targets named in the cited records: GLP-1 receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA125469, marketed as TRULICITY). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Dulaglutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- LY2189265
- Trulicity
Where this page sits
Research records
Cited research records for Dulaglutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Semaglutide — Incretin receptor agonists
- Liraglutide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Dulaglutide?
Dulaglutide is a GLP-1 analogue fused to a modified immunoglobulin Fc fragment, a fusion protein rather than a peptide; PubChem returned no compound record for the name. The Drugs@FDA register returned an approved biologics application under this generic name, which is recorded in the regulatory status field and is not what this page describes.
Which class is Dulaglutide indexed under?
Dulaglutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Dulaglutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA125469, marketed as TRULICITY). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA125469. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:dulaglutide
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes care (2014). pmid:24842985
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes care (2014). pmid:24742660
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes care (2014). pmid:24879836
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet (London, England) (2014). pmid:25018121
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes care (2015). pmid:26089386
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology (2018). pmid:29483060
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England) (2019). pmid:31189511
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet (London, England) (2019). pmid:31189509
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. The Lancet. Neurology (2020). pmid:32562683
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet. Diabetes & endocrinology (2018). pmid:29910024
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology (2018). pmid:29397376
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.